Scarica l'app Stockscreener
15.50
0.26%
0.04
Dopo l'orario di chiusura:
15.09
-0.41
-2.65%
Precedente Chiudi:
$15.46
Aprire:
$15.11
Volume 24 ore:
1.26M
Relative Volume:
1.72
Capitalizzazione di mercato:
$1.42B
Reddito:
$247.00M
Utile/perdita netta:
$-249.00M
Rapporto P/E:
-3.9141
EPS:
-3.96
Flusso di cassa netto:
$-267.00M
1 W Prestazione:
-3.61%
1M Prestazione:
+6.02%
6M Prestazione:
-4.26%
1 anno Prestazione:
-9.30%
Intervallo 1D:
$15.10
$15.99
Intervallo di 1 settimana:
$14.78
$16.54
Portata 52W:
$13.52
$20.31
Arcus Biosciences Inc Stock (RCUS) Company Profile
Nome
Arcus Biosciences Inc
Settore
Industria
Telefono
(510) 694-6200
Indirizzo
3928 POINT EDEN WAY, HAYWARD, CA
Confronta RCUS con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
RCUS
Arcus Biosciences Inc
|
15.50 | 1.42B | 247.00M | -249.00M | -267.00M | -3.09 |
|
VRTX
Vertex Pharmaceuticals Inc
|
397.27 | 102.31B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
701.85 | 77.13B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
623.82 | 37.30B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
245.44 | 31.66B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
113.08 | 27.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Arcus Biosciences Inc Stock (RCUS) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-10-21 | Iniziato | H.C. Wainwright | Neutral |
| 2024-10-08 | Iniziato | Wells Fargo | Overweight |
| 2022-11-18 | Iniziato | BofA Securities | Neutral |
| 2022-10-11 | Iniziato | Morgan Stanley | Overweight |
| 2021-10-15 | Ripresa | BTIG Research | Buy |
| 2020-11-24 | Iniziato | Berenberg | Buy |
| 2020-11-23 | Iniziato | Evercore ISI | Outperform |
| 2020-04-03 | Iniziato | Cantor Fitzgerald | Overweight |
| 2020-03-04 | Iniziato | Barclays | Overweight |
| 2019-11-12 | Iniziato | SunTrust | Buy |
| 2019-09-27 | Iniziato | Mizuho | Buy |
| 2019-05-24 | Ripresa | Citigroup | Buy |
| 2018-10-09 | Iniziato | Wedbush | Outperform |
| 2018-04-09 | Iniziato | Citigroup | Buy |
| 2018-04-09 | Iniziato | Goldman | Neutral |
| 2018-04-09 | Iniziato | Leerink Partners | Outperform |
Mostra tutto
Arcus Biosciences Inc Borsa (RCUS) Ultime notizie
Shareholders in Arcus Biosciences (NYSE:RCUS) have lost 65%, as stock drops 9.9% this past week - Yahoo Finance
Arcus Biosciences, Inc. (NYSE:RCUS) Shares Bought by Jane Street Group LLC - MarketBeat
State Street Corp Trims Stake in Arcus Biosciences, Inc. (NYSE:RCUS) - MarketBeat
Arcus Biosciences to Present at J.P. Morgan Healthcare Conference 2025Key Oncology Updates Expected - StockTitan
UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Sells 26,966 Shares of Arcus Biosciences, Inc. (NYSE:RCUS) - Defense World
BNP Paribas Financial Markets Has $173,000 Stock Holdings in Arcus Biosciences, Inc. (NYSE:RCUS) - Defense World
(RCUS) Trading Advice - Stock Traders Daily
Arcus Biosciences' SWOT analysis: stock outlook amid HIF2alpha and TIGIT progress - Investing.com
Estimating The Intrinsic Value Of Arcus Biosciences, Inc. (NYSE:RCUS) - Simply Wall St
Charles Schwab Investment Management Inc. Has $8.67 Million Stock Position in Arcus Biosciences, Inc. (NYSE:RCUS) - MarketBeat
Arcus Biosciences Announces New Employment Inducement Grants - Marketscreener.com
Arcus Biosciences Awards New Employee Equity Grants Under Inducement Plan - StockTitan
Fmr LLC Boosts Holdings in Arcus Biosciences, Inc. (NYSE:RCUS) - MarketBeat
Point72 Asset Management L.P. Increases Stake in Arcus Biosciences, Inc. (NYSE:RCUS) - MarketBeat
(RCUS) Investment Analysis and Advice - Stock Traders Daily
Arcus Biosciences' chief accounting officer sells $3,079 in stock - Investing.com
Arcus Biosciences' chief accounting officer sells $3,079 in stock By Investing.com - Investing.com Canada
Parkman Healthcare Partners LLC Acquires 610,219 Shares of Arcus Biosciences, Inc. (NYSE:RCUS) - MarketBeat
Arcus Biosciences Grants New Employee Stock Options and RSUs in Latest Inducement Awards - StockTitan
Walleye Capital LLC Makes New Investment in Arcus Biosciences, Inc. (NYSE:RCUS) - MarketBeat
Biotech Advances Drive Cancer Research as Global Rates Continue Upward Trend - Benzinga
Arcus Biosciences, Inc. (NYSE:RCUS) Given Average Rating of "Buy" by Analysts - MarketBeat
Suvretta Capital Management LLC Trims Position in Arcus Biosciences, Inc. (NYSE:RCUS) - MarketBeat
Algert Global LLC Has $1.73 Million Position in Arcus Biosciences, Inc. (NYSE:RCUS) - MarketBeat
Arcus up 4% following Merck Welireg kidney cancer data - MSN
When (RCUS) Moves Investors should Listen - Stock Traders Daily
BNP PARIBAS ASSET MANAGEMENT Holding S.A. Has $14.24 Million Stake in Arcus Biosciences, Inc. (NYSE:RCUS) - MarketBeat
RCUS (Arcus Biosciences) Cash-to-Debt : 18.78 (As of Sep. 2024) - GuruFocus.com
Arcus Biosciences, Inc.'s (NYSE:RCUS) Price Is Right But Growth Is Lacking - Simply Wall St
Arcus Biosciences, Inc. (NYSE:RCUS) Q3 2024 Earnings Call Transcript - MSN
Arcus Biosciences to Present at Evercore and Citi Healthcare Conferences in December | RCUS Stock News - StockTitan
Arcus Biosciences' SWOT analysis: biotech stock faces pivotal data releases - Investing.com
Arcus Biosciences' SWOT analysis: biotech stock faces pivotal data releases By Investing.com - Investing.com Australia
FMR LLC Bolsters Stake in Arcus Biosciences Inc - GuruFocus.com
Arcus Biosciences Awards Key Equity Grants to New Hires at $17.85 Per Share | RCUS Stock News - StockTitan
GSA Capital Partners LLP Raises Stock Holdings in Arcus Biosciences, Inc. (NYSE:RCUS) - MarketBeat
FY2024 Earnings Forecast for RCUS Issued By HC Wainwright - MarketBeat
Analysts Have Made A Financial Statement On Arcus Biosciences, Inc.'s (NYSE:RCUS) Third-Quarter Report - Yahoo Finance
Arcus Biosciences, Inc. (RCUS) Reports Q3 Loss, Tops Revenue Estimates - MSN
Arcus Biosciences (NYSE:RCUS) Posts Earnings Results, Beats Expectations By $0.06 EPS - MarketBeat
Arcus Biosciences Inc (RCUS) Q3 2024 Earnings Call Highlights: S - GuruFocus.com
Arcus Biosciences Inc (RCUS) Q3 2024 Earnings Call Highlights: Strong Cash Position and ... - Yahoo Finance
Arcus Biosciences, Inc. (NYSE:RCUS) Receives Average Rating of “Buy” from Analysts - Defense World
Analysts Set Arcus Biosciences, Inc. (NYSE:RCUS) Price Target at $33.67 - MarketBeat
Arcus Biosciences, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Arcus Biosciences Surges: 34% Cancer Trial Success, AstraZeneca Deal Boosts Q3 | RCUS Stock News - StockTitan
Arcus Biosciences (NYSE:RCUS) Receives "Neutral" Rating from HC Wainwright - MarketBeat
Expert Outlook: Arcus Biosciences Through The Eyes Of 8 Analysts - Benzinga
Arcus says Gilead-partnered cancer therapy cut death risk by 36% - Seeking Alpha
Arcus reports improved survival with cancer drug combo - Investing.com
Arcus Biosciences (RCUS) Announces that Domvanalimab Plus Zimberelimab Improved Overall Survival in ARC-10 - StreetInsider.com
Arcus Biosciences Inc Azioni (RCUS) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
2.88%
2.65%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):